期刊文献+

uPA-uPAR拼接结合变化与肝硬化患者恶变趋势的相关性研究

Correlation between uPA-uPAR Splicing Combination Changes and Aggravations in Liver Cirrhosis Patients
下载PDF
导出
摘要 目的 探讨引起尿激酶型纤溶酶原激活物及其可溶型受体比值(uPA/suPAR)及uPA-uPAR拼接结合的变化与肝硬化恶变趋势的相关性.方法 选择2008年8月~2010年4月肝硬化初诊患者133例,经3年随访后分为病情稳定组和恶变组,应用酶联免疫法(ELISA)检测其血浆中uPA和suPAR水平,采用免疫组化法检测初诊患者、恶变组的uPA及其受体(uPAR)在组织中的表达.结果 肝硬化恶变组uPA/suPAR值较稳定组患者有显著升高,差异有统计学意义(t=5.626,P=0.00〈0.05);肝硬化初诊患者与稳定组比较差异无统计学显著性意义(t=1.19,P=0.24〉0.05).uPA和uPAR在恶变组患者组织中的阳性表达率比初诊患者明显增高,比较差异均有统计学意义(χ2=5.443~6.091,P值均〈0.05).结论 uPA/suPAR比值的变化可能存在uPA-uPAR拼接变异体结合的改变,其与肝硬化患者恶变趋势密切相关. Objective To explore the correlation between the changes of uPA/suPAR ratio,uPA-uPAR splicing combination and the aggravations in liver cirrhosis patients. Methods Selected 133 case of first diagnosis liver cirrhosis patients, they were divided into stable group and malignant group after three years follow-up,and used the ELISA method for detecting the plasma uPA,suPAR levels and the immunohistochemieal method for detecting the expression of uPA, uPAR in their tissues. Results The uPA/suPAR ratio of the cirrhosis malignant group was significantly higher than that in stable group (t= 5. 626, P=0. 00〈0. 05). Compared with two groups between the first diagnosis liver cirrhosis patients and the stable group, there was no significant statistical significance difference (t= 1.19, P= 0. 24〉0. 05). The uPA, uPAR positive expression rate in the malignant group was significantly higher than that in the initial diagnosis patients with liver cirrhosis, compared with the differences between the two groups, there was statistically significant (X^2 = 5. 443 - 6. 091, P〈0.05). Conclusion The change of uPA/suPARratio maybe caused by the change of uPA-uPAR splice varients which is close related to the ag-gravations in liver cirrhosis.
出处 《现代检验医学杂志》 CAS 2013年第5期75-76,80,共3页 Journal of Modern Laboratory Medicine
基金 广西科学基金资助项目(桂科基:0731067).
关键词 肝硬化 尿激酶型纤溶酶原激活物 尿激酶型纤溶酶原激活物可溶型受体 uPA-uPAR拼接变异 liver cirrhosis urokinase-type plaminogen activator soluble receptor of urokinase-type plaminogen activator uPA-uPAR splicing variation
  • 相关文献

参考文献10

  • 1Dass K, Ahmad A, Azmi AS, et al. Evolving role of uPA/uPAR system in human cancers l-J]. Cancer Treatment Reviews, 2008,34 (2) : 122-136.
  • 2Zimmermann HW,Reuken PA,Koeh A,et al. Soluble urokinase plasminogen activator receptor is compart- mentally regulated in decompensated cirrhosis and in- dicates immune activation and short-term mortality [J]. Journal of Internal Medicine, 2013,274 (1): 86- 100.
  • 3詹灵凌,吕小平,李山,姜海行,覃锦耀,唐劲光.肝硬化患者血浆uPA、uPAR水平与肝纤维化和癌变的相关性[J].临床检验杂志,2008,26(2):144-145. 被引量:8
  • 4Sloand EM, Pfannes L, Scheinberg P, et al. Increased soluble urokinase plasminogen activator receptor (su-PAR) is associated with thrombosis and inhibition of plasmin Generation in paroxysmal nocturnal hemo- globinuria (PNH) patients[J]. Experimental Hema- tology,2008,36(12) : 1616-1624.
  • 5Almasi CE, Hyer-Hansen G, Christensen IJ, et al. Prognostic impact of liberated domain I of the uroki- nase plasminogen activator receptor in squamous cell lung cancer tissue[J]. Lung Cancer, 2005,48 (3) : 349- 355.
  • 6Almasi CE, Hyer-Hansen G, Christensen IJ, et al. Prognostic significance of urokinase plasminogen ac- tivator receptor and its cleaved forms in blood from patients with non-small cell lung cancer[J]. APMIS, 2009,117 (10) : 755-761.
  • 7Stewart CE, Sayers I. Charaeterisation of urokinase plasminogen activator receptor variants in human air- way and peripheral eeUs[J]. BMC Molecular Biology, 2009,10(1) : 75.
  • 8Stephens RW, PUnen J, Tapiovaara H, et al. Activa- tion of pro-urokinase and plasminogen on human sar- coma eells a proteolytie system with surface-bound reactants[J]. J Cell Biol, 1989,108(5) : 1987-1995.
  • 9詹灵凌,吕小平,李山,姜海行.尿激酶型纤溶酶原激活物的表达与慢性重型肝炎预后的相关性[J].临床肝胆病杂志,2007,23(3):170-171. 被引量:2
  • 10孙继兴,杨雅静,周秀艳,宋扬.恶性肿瘤患者血清胱抑素C和可溶性尿激酶受体检测的临床意义[J].中国肿瘤临床,2009,36(24):1381-1383. 被引量:2

二级参考文献22

共引文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部